IMRA

IMARA Inc. [IMRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMRA Stock Summary

Top 10 Correlated ETFs

IMRA

Top 10 Correlated Stocks

IMRA

In the News

IMRA Financial details

Company Rating
-
Market Cap
165.8M
Income
-5.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
04 May 2023
P/E
7087.8
Forward P/E
-
PEG
-467.44
P/S
-
P/B
401.53
P/C
-
P/FCF
-4.2
Quick Ratio
26.7
Current Ratio
27.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.88
EPS next Y
-
EPS next Q
-
EPS this Y
-102.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
25%
-
-
-
-
SMA20
-12.89%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
5%
ROE
13%
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.9739-6.32
52W High
-
52W Low
-
RSI
47.17
Rel Volume
0.05
Avg Volume
116.26K
Volume
6.23K
Perf Week
3.55%
Perf Month
-6.38%
Perf Quarter
-
Perf Half Y
12.28%
-
-
-
-
Beta
1.08129
-
-
Volatility
1.1%, 4.86%
Prev Close
-1.3%
Price
50.76
Change
-2.87%

Something similar

Top by Market Cap
EMBASSY.NS
GOOG
VTI
V
M&M.NS
Top Correlated ETFs
IUSW.DE
XGLF.DE
5BTS.MI
IUSS.DE
PFFR
Top Correlated Stocks
BAH
0HOT.L
DECK
AMC.WA
CPRT
Similar Market Cap
2700.HK
GEM.L
MCB.L
ANGO
NRO

Company Profile

Healthcare Biotechnology
  • Volume Average 116.26K
  • Market Capitalization 165.8M
  • Employee 41
  • CEO Dr. Rahul D. Ballal Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2020-03-12
  • Website https://imaratx.com

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.